Iambic, an AI-driven biotech, closed an oversubscribed financing of more than $100 million to advance its portfolio of AI-discovered therapeutics and platform capabilities. The round drew participation from investors including ARK, Regeneron Ventures, Illumina Ventures and others listed in the company’s release. Iambic plans to deploy capital to accelerate clinical programs—among them a brain-penetrant HER2 TKI—and to fund partnerships and technology development. The company recently announced collaborations that combine its NeuralPLexer model with external drug developers. Investors signaled continued appetite for AI-native biotechs that translate in silico discovery into clinic-ready assets; Iambic’s raise underscores growth capital availability for platform-first drug developers.